Pazopanib in Soft Tissue Sarcomas

IF 0.7 1区历史学 Q1 HISTORY Oral History Review Pub Date : 2020-01-01 DOI:10.17925/ohr.2020.16.1.15

B. V. Tine

引用次数: 0

Abstract

Support: No funding was received in the publication of this article. Soft tissue sarcomas represent a group of over 80 rare malignant tumors that arise from tissues of mesenchymal origin throughout the body. Advanced soft tissue sarcoma is treated with single-agent or combination systemic chemotherapy, but is associated with a poor prognosis. Pazopanib (Votrient, Novartis, Basel, Switzerland) is an oral multitarget tyrosine kinase inhibitor that has received regulatory approval as a second-line and beyond treatment for metastatic soft tissue sarcoma based on the findings of the phase III PALETTE study (ClinicalTrials.gov identifier: NCT00753688). However, there is a population of elderly and debilitated patients with soft tissue sarcoma who are not fit for standard first-line chemotherapy that is anthracycline-based. As pazopanib is well tolerated with minimal side effects, a phase II study (ClinicalTrials.gov identifier: NCT02300545) investigated the use of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

帕唑帕尼在软组织肉瘤中的应用

支持:本文的出版未收到任何资助。软组织肉瘤是一组80多种罕见的恶性肿瘤，起源于全身的间质组织。晚期软组织肉瘤可采用单药或联合全身化疗，但预后较差。Pazopanib (Votrient, Novartis, Basel, Switzerland)是一种口服多靶点酪氨酸激酶抑制剂，基于III期PALETTE研究(ClinicalTrials.gov标识号:NCT00753688)的结果，已获得监管部门批准，作为转移性软组织肉瘤的二线及以上治疗药物。然而，有一群老年人和衰弱的软组织肉瘤患者不适合标准的一线化疗，即蒽环类药物。由于pazopanib具有良好的耐受性和最小的副作用，一项II期研究(ClinicalTrials.gov identifier: NCT02300545)调查了pazopanib作为不适合化疗的不可切除或转移性软组织肉瘤患者的一线治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oral History Review Multiple-

CiteScore

1.20

自引率

27.30%

发文量

期刊介绍： The Oral History Review, published by the Oral History Association, is the U.S. journal of record for the theory and practice of oral history and related fields. The journal’s primary mission is to explore the nature and significance of oral history and advance understanding of the field among scholars, educators, practitioners, and the general public. The Review publishes narrative and analytical articles and reviews, in print and multimedia formats, that present and use oral history in unique and significant ways and that contribute to the understanding of the nature of oral history and memory. It seeks previously unpublished works that demonstrate high-quality research and that offer new insight into oral history practice, methodology, theory, and pedagogy. Work published in the journal arises from many fields and disciplines, reflecting the interdisciplinary nature of oral history. While based in the U.S., the Review reflects the international scope of the field and encourages work from international authors and about international topics.

期刊最新文献

Labor under Siege: Big Bob McEllrath and the ILWU’s Fight for Organized Labor in an Anti-Union Era Hurricane Sandy on New Jersey’s Forgotten Shore Light the Road of Freedom: Women’s Voices from Gaza Surfing the South: The Search for Waves and the People Who Ride Them Our Work is Everywhere: An Illustrated Oral History of Queer and Trans Resistance